These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 9226741

  • 21. [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man].
    Morita S, Irie Y, Sakuragi S, Kori H.
    Nihon Yakurigaku Zasshi; 1977 Mar; 73(2):229-35. PubMed ID: 328355
    [Abstract] [Full Text] [Related]

  • 22. Ocular distribution of carteolol after single and repeated ocular instillation in pigmented rabbits.
    Fujio N, Kusumoto N, Odomi M.
    Acta Ophthalmol (Copenh); 1994 Dec; 72(6):688-93. PubMed ID: 7747576
    [Abstract] [Full Text] [Related]

  • 23. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S, Tagawa M, Amejima H, Nakao M, Kagemoto A, Fujii T, Miyazaki H, Sekine Y.
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [Abstract] [Full Text] [Related]

  • 24. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T, Carteolol Long-acting Formulation Study Group.
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Improvement of the ocular bioavailability of carteolol by ion pair.
    Higashiyama M, Tajika T, Inada K, Ohtori A.
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):333-9. PubMed ID: 17076627
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of carteolol in patients with impaired renal function.
    Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y.
    Eur J Clin Pharmacol; 1992 Oct; 43(4):417-21. PubMed ID: 1451723
    [Abstract] [Full Text] [Related]

  • 28. Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.
    Martins ML, Pierossi MA, Moraes LA, Ribeiro W, Abbib Júnior E, Mendes GB, Poli A, De Nucci G, Muscará MN.
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):324-8. PubMed ID: 9266287
    [Abstract] [Full Text] [Related]

  • 29. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S, Venkatesh P, Mullangi R, Srinivas NR.
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 31. [Effect of 8-hydroxycarteolol in normal human eyes].
    Kato Y, Sasaki T, Tsukahara S.
    Nippon Ganka Gakkai Zasshi; 1992 Jul; 96(7):899-903. PubMed ID: 1354411
    [Abstract] [Full Text] [Related]

  • 32. Time course of changes in ocular aberrations after instillation of carteolol long-acting solution and timolol gel-forming solution.
    Hiraoka T, Daito M, Okamoto F, Kiuchi T, Oshika T.
    J Ocul Pharmacol Ther; 2011 Apr; 27(2):179-85. PubMed ID: 21314439
    [Abstract] [Full Text] [Related]

  • 33. The effects of dose, route, and repeated dosing on the disposition and kinetics of tetrabromobisphenol A in male F-344 rats.
    Kuester RK, Sólyom AM, Rodriguez VP, Sipes IG.
    Toxicol Sci; 2007 Apr; 96(2):237-45. PubMed ID: 17234645
    [Abstract] [Full Text] [Related]

  • 34. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats.
    Gáll Z, Vancea S, Szilágyi T, Gáll O, Kolcsár M.
    Eur J Pharm Sci; 2015 Feb 20; 68():106-13. PubMed ID: 25530452
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species.
    Bruzzese T, Rimaroli C, Bonabello A, Mozzi G, Ajay S, Cooverj ND.
    Arzneimittelforschung; 2000 Jan 20; 50(1):60-71. PubMed ID: 10683718
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
    Boberg M, Ahr HJ, Beckermann B, Bühner K, Siefert HM, Steinke W, Wünsche C, Hirayama M.
    Arzneimittelforschung; 1997 Aug 20; 47(8):928-38. PubMed ID: 9296279
    [Abstract] [Full Text] [Related]

  • 37. The possible treatment of migraine with carteolol hydrochloride.
    Shapiro MK, Gorn R.
    Headache; 1999 Feb 20; 39(2):138-9. PubMed ID: 18567128
    [No Abstract] [Full Text] [Related]

  • 38. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K, Chaluvadi MR, Mullangi R, Mamidi NV, Srinivas NR.
    Biopharm Drug Dispos; 2004 Oct 20; 25(7):323-8. PubMed ID: 15386480
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys.
    Kamimura H, Sasaki H, Kawamura S.
    Xenobiotica; 1984 Aug 20; 14(8):613-20. PubMed ID: 6149656
    [Abstract] [Full Text] [Related]

  • 40. [Toxicology of carteolol].
    Lang W.
    Arzneimittelforschung; 1983 Aug 20; 33(2a):290-6. PubMed ID: 6682320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.